IPR Paper (Question and Answer)
via https://youtu.be/SK6dhBxDsL8
Posts
The Placement Cell of SVKM's Dr BNCP presents Placement Brochure Theme Competition
via https://youtu.be/4AetN1YUnLQ
Pharma Literati internship opportunities - Nov 2020
Google form - https://docs.google.com/forms/ d/1Y9PPWcL- kZjIho3jj4koWkTTwpoiog8u8JW- o2QLmi4/viewform?edit_ requested=true
Inaugural session of Batch 2 of Quality by Design course by Pharma Literati
via https://youtu.be/M5yQ-pb24fc
QUALITY BY DESIGN COURSE - BATCH 2 ANNOUNCEMENT - STARTING 12TH OCTOBER 2020
via https://youtu.be/EmjdVJLnuYY
Short term 2 week certificate course on QBD
Register at - https://docs.google.com/forms/d/1hRv58nZJuNYTGl9dcliCTwsf3zgrwSv5VL5lPkdPBpA/edit
Certificate course on 'Patenting and commercializtion of Herbal products' - Apply by 15th October
Registration link - https://docs.google.com/forms/d/1dRmMXTDYVnnt7tcHcgCpikbD5v4P4C5HLUO_sS3B97A/edit
Webinar on 'Quality by Design in Pharmaceutical Industry' on 20th September 2020 - Free registration
Registration link - https://docs.google.com/forms/d/1pp8_UQMWY0jzVc1U7KQ74wFLy3WhijjXppRRmFNeD3Y/edit
Partnership opportunities at Pharma Literati
We at Pharma Literati are looking forward to partnership opportunities from academic institutes for conduct of webinars, conferences and value added courses with the industry experts. Write an email to pharmaliterati @gmail.com to know more.
Start-up express at P.E.S's Rajaram & Tarabai Bandekar College of Pharmacy
via https://youtu.be/EVBZxqu_c-4
Open Science: Key to combat zoonosis
Largely opaque and proprietary R&D environments in the life sciences sector need to make way for strategies facilitated by sustainable investment models, open sourcing and multi-lateral partnerships, to deal with a growing threat from infectious/zoonosis diseases “There are decades where nothing happens, and there are weeks where decades happen.” These words by Russian revolutionary, Vladimir Lenin describe the current scenario to a ‘T’. Most of us have seen more disruptions over the last few weeks than probably ever before in our lifetime, especially if one is a millennial or younger. Yet, these times are also a watershed in terms of the lessons for mankind. The impact and implications of the coronavirus pandemic will shape new norms and mindsets, approaches and agendas worldwide for a long time to come. Hopefully, it will also usher a more cohesive approach to the way we practise and publish scientific research. Because it is critical, especially in the life science
FICCI launches first international ‘Virtual Healthcare and Hygiene Expo 2020’
Dr Sangita Reddy, President, FICCI announced the launch of ‘Virtual Healthcare and Hygiene Expo 2020’ (VH&H Expo 2020) – India’s first International virtual exhibition and conference organized by FICCI from 22-26 June 2020. This is the first time that an event will be organised on virtual platform and digitally accessed by buyers from across the globe. The first edition of VH&H Expo 2020 will comprise of five-day comprehensive virtual exhibition on sectors like AYUSH & Wellness, Medical Devices, Medical Textiles and Consumables, Pharmaceuticals and Sanitization. The virtual event will also feature webinars and discuss various issues and opportunities in focus sectors, post COVID-19. Dr Reddy said, “ COVID-19 is one of the biggest disaster mankind has ever faced in recent times, bringing disruption to the human life worldwide. With no vaccine or treatment currently in place, containment and social distancing has become the only solution to prevent the spread of hig
Glenmark initiates Phase 3 clinical trials on Favipiravir to check efficacy on COVID-19 patients.
Glenmark Pharmaceuticals on Tuesday said it has initiated Phase 3 clinical trials on antiviral drug Favipiravir to check its efficacy on COVID-19 patients in India. The Mumbai-based company had received approval from Drug Controller General of India (DCGI) last month to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients. Glenmark Pharmaceuticals is the first company in the country to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India, it said in a statement. Clinical trials have commenced and over ten leading government and private hospitals are being enrolled for the study, it added. Glenmark estimates study completion by July/August 2020, it said. As per the approved clinical trial protocol, 150 subjects with mild to moderate COVID-19 symptoms will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care. Treatment dura
CDSCO to assess issues in the procurement and prices of APIs
Reportedly, prices of APIs/KSMs for hydroxychloroquine, azithromycin and paracetamol have increased exponentially in the last three months The National Pharmaceuticals Pricing Authority (NPPA) has asked the Central Drugs Standard Control Organisation (CDSCO) to assess procurement and price issues regarding APIs for hydroxychloroquine, azithromycin and paracetamol. Following that, the CDSCO has issued a letter to all the States and Union Territories drug controller to understand the issues regarding the same for APIs and key starting materials (KSM) in the country. This step is being taken by the authorities after media reports and representation by different pharma associations about the surge in the prices of APIs in the country. Dr Hemant Koshia, Commissioner, FDCA said, “We have also come to know about the increase in the prices of these APIs in the market. And it happened because some traders and small manufacturers have spiked their prices by almost 10 per cent. And, con
How to prepare for NIPER entrance examination - Video by experts
Pharma Literati had an opportunity to host 3 of the sharpest minds at NIPER who guided the students about how to prepare for NIPER examination. The video for same is available at https://www.youtube.com/watch?v=bLjtBy0D-rk&t=2727s
Live session on 'How to prepare for NIPER 2020' with experts from NIPER for FREE !!!
Register at: https://docs.google.com/forms/d/1IHxxqOxkJu3fbYbTJ6ub5LiUkvucPRjpietNn6cgYiA/edit
Webinar on 'Career opportunities as patent agent' - 26th April 2020
Registrations link - https://docs.google.com/forms/d/1UCC1L3r_yMCXoIbink9A-M2E9di2q7RA9L2W49GJmsk/edit
Vaccines under clinical trials to prevent Covid-19 - An article by Aliva Basu
The author is B. Pharm student from NMIMS-SPPSPTM Introduction Covid-19 or also known as Coronavirus disease is an infectious disease which has rapidly emerged to become a global pandemic. The main reasons why it is so dangerous is because it takes about 2 weeks for the symptoms (coughing, fever and in severe cases, respiratory distress) to develop and thus be identified. In that period, the infected person can transmit this disease to countless other people they come in contact with through cough or sneeze droplets. [1] Another reason for it’s danger lies in the survival mechanism of the virus causing the disease. Covid-19 is caused by the virus SARS-CoV-2 . This virus can remain stable and alive for several days on surfaces and in aerosols. [2] The exact mechanism for this disease is yet not known and is still under research but there are several theories proposed. The pandemic is a huge risk to global health with more than 1,500,000 cases reported worldwide till dat